Contribution: Industrial Research Assistance Program – Contributions to Firms
Arch Biopartners Inc.
$4,000,000.00
LSALT Drug Development program to mitigate COVID-19 related Organ (Lung and Kidney) damage and inflammation
EF 2022-23 · 2022-11-01
Résumé
The project targets the prevention of acute organ inflammation injury in the lungs and kidneys of patients who have moderate to severe COVID-19 and other diseases. LSALT peptide is a novel drug candidate and selective dipeptidase-1 inhibitor which blocks injury in the lungs and kidneys by reducing leukocyte recruitment and inflammation in these organs.
This project focuses on completing the clinical and commercial drug development tasks needed to obtain regulatory approval for LSALT peptide. A successful project will advance the LSALT peptide as a new therapeutic that will reduce organ inflammation complications in high risk patients, increase survival rates and provide resiliency in the Canadian healthcare system for future pandemics.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Toronto|Toronto, Ontario, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
101328227
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Modifications
Chaque version de l'entente telle que publiée, de la plus ancienne à la plus récente, avec son total à cette version. Le montant ci-dessus est le plus récent.
| Modification | Date | Exercice financier | Total |
|---|---|---|---|
| 0 | 2022-11-01 | 2022-23 | $4,000,000.00 |
| 1 | 2022-11-01 | 2022-23 | $4,000,000.00 |
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 60 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 60 jours.
Agreement End Date
2024-03-31
Agreement Number
1003639
Agreement Start Date
2022-11-01
Agreement Title
LSALT Drug Development program to mitigate COVID-19 related Organ (Lung and Kidney) damage and inflammation
Agreement Title (French)
Programme de développement de médicaments LSALT pour atténuer les lésions et l’inflammation des organes (poumons et reins) liées à la COVID-19
Agreement Type
Contribution
Agreement Value
$4,000,000.00
Amendment Date
2024-01-29
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The project targets the prevention of acute organ inflammation injury in the lungs and kidneys of patients who have moderate to severe COVID-19 and other diseases. LSALT peptide is a novel drug candidate and selective dipeptidase-1 inhibitor which blocks injury in the lungs and kidneys by reducing leukocyte recruitment and inflammation in these organs.
This project focuses on completing the clinical and commercial drug development tasks needed to obtain regulatory approval for LSALT peptide. A successful project will advance the LSALT peptide as a new therapeutic that will reduce organ inflammation complications in high risk patients, increase survival rates and provide resiliency in the Canadian healthcare system for future pandemics.
Description (French)
Le projet vise à prévenir les lésions inflammatoires aiguës des organes dans les poumons et les reins des patients atteints d’une forme modérée à grave de la COVID-19 et d’autres maladies. Le peptide LSALT est un nouveau médicament candidat et un inhibiteur sélectif de la dipeptidase-1 qui bloque les lésions dans les poumons et les reins en réduisant le recrutement des leucocytes et l’inflammation dans ces organes. Ce projet se concentre sur la réalisation des tâches cliniques et commerciales de développement de médicaments nécessaires pour obtenir l’approbation réglementaire du peptide LSALT. La réussite du projet permettra de faire progresser le peptide LSALT en tant que nouvelle thérapeutique qui réduira les complications liées à l’inflammation des organes chez les patients à haut risque, augmentera les taux de survie et assurera la résilience du système de santé canadien en cas de pandémies futures.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Toronto--St. Paul's
Federal Riding (French)
Toronto--St. Paul's
Federal Riding Number
35090
NAICS Code
334512
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
101328227
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Arch Biopartners Inc.
Recipient Postal Code
M4T 2M5
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2022-2023-Q4-1003639
